Amneal Pharmaceuticals Inc. Earnings

Amneal Pharmaceuticals Inc.’s revenue jumped 5.5% since last year same period to $695.42Mn in the Q1 2025. On a quarterly growth basis, Amneal Pharmaceuticals Inc. has generated -4.8% fall in its revenue since last 3-months.

Amneal Pharmaceuticals Inc.’s net profit jumped 126.86% since last year same period to $24.62Mn in the Q1 2025. On a quarterly growth basis, Amneal Pharmaceuticals Inc. has generated 179.21% jump in its net profits since last 3-months.

Amneal Pharmaceuticals Inc.’s net profit margin jumped 125.46% since last year same period to 3.54% in the Q1 2025. On a quarterly growth basis, Amneal Pharmaceuticals Inc. has generated 183.2% jump in its net profit margins since last 3-months.

Amneal Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.15 - a -3.55% fall from last quarter’s estimates.

Amneal Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at 0.15.

Amneal Pharmaceuticals Inc.’s earning per share (EPS) jumped 50% since last year same period to 0.21 in the Q1 2025. This indicates that the Amneal Pharmaceuticals Inc. has generated 50% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Amneal Pharmaceuticals Inc.’s return on assets (ROA) stands at 0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Amneal Pharmaceuticals Inc.’s return on equity (ROE) stands at -8.81.